Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Exclusion Criteria

• •History of anaphylactic reaction or asthma
• •Unknown pregnancy or positive serum/urine pregnancy test
• •Currently breastfeeding a child
• •Chronic illness, that in the opinion of the investigator, is at a stage that could interfere with trial conduct or completion
• •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
• •Planned participation in another clinical trial during the present trial period
• •Known or suspected congenital or acquired immunodeficiency, receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• •Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
• •Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
• •Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
• •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for pandemic influenza vaccination which may be received at least two weeks before the study vaccines
• •Planned receipt of any vaccine in the 4 weeks following the trial vaccination, except for pandemic influenza vaccination in the event of a local or national immunization program
• •Known seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
• •Laboratory confirmed/self-reported thrombocytopenia contraindicating intramuscular (IM) vaccination
• •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• •Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data
• •Previous vaccination against pneumococcal disease (in the previous 5 years)
• •History of pneumococcal infection (confirmed either clinically, serologically, or microbiologically) within 5 years
• •At high risk for pneumococcal infection during the trial
• •Living in a household with children \<5 years of age.